Background--Moderate aortic stenosis (MAS) has not been extensively studied and characterized, as no published study has been specifically devoted to this condition.
A ortic stenosis (AS) is the most common valvular heart disease in developed countries, and its prevalence is increasing with aging of the population.
1,2 Several long-term follow-up series [3] [4] [5] have now clearly defined the diagnosis and management of severe AS, and guidelines have now been established. 6, 7 However, moderate AS (MAS) has not been extensively studied and clearly characterized. Although some studies focusing on mild-to-moderate AS have shown an increased incidence of cardiovascular events, 8 strongly influenced by comorbidities, 9, 10 no study has been specifically devoted to MAS. Furthermore, no data are available about the prognosis of MAS compared with the general population. The aim of this study was, therefore, to focus on MAS to describe the characteristics of this population and evaluate the longterm survival of these patients compared with that of the general population. This study included patients with a diagnosis of AS established in the echocardiography laboratories of 2 French tertiary centers (Amiens and Lille). MAS was defined as an aortic valve area (AVA) measured by echocardiography between 1 and 1.5 cm 2 .
Methods Inclusion and Exclusion Criteria
The data that support the findings of this study are available from the corresponding author on reasonable request. Between 2000 and 2014, patients aged ≥18 years with a diagnosis of at least mild AS (aortic valve calcification with restricted systolic leaflet motion and AVA <2 cm 2 ) and left ventricular ejection fraction (LVEF) ≥50% were prospectively identified and included in an electronic database. The following patients were excluded: (1) individuals with more than mild aortic and mitral regurgitation; (2) patients with prosthetic valves, congenital heart disease (with the exception of bicuspid aortic valves), supravalvular or subvalvular AS, or dynamic left ventricular (LV) outflow tract obstruction; and (3) individuals who declined to participate in the study. The present analysis focused on 508 patients with MAS (defined as AVA ≤1.5 and ≥1 cm 2 ). All comorbidities were collected from medical records. The Charlson comorbidity index, comprising the sum of individual comorbidities, was calculated for each patient.
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All subjects gave informed consent. This study was approved by an independent ethics committee and was conducted in accordance with institutional policies, French legislation, and the revised Declaration of Helsinki.
Echocardiography
All patients underwent a comprehensive Doppler-echocardiographic assessment, using commercially available ultrasound systems. Aortic flow was systematically recorded using continuous-wave Doppler on several views (apical 5 chamber, right parasternal, suprasternal, and epigastric). The view identifying the highest velocities was used to determine peak aortic jet velocity. Three consecutive measurements obtained on this view in patients in sinus rhythm and 5 consecutive measurements in patients in atrial fibrillation (AF) were systematically averaged. The alignment of both pulsed-and continuous-wave Doppler was optimized to be parallel with flow. Pressure gradients were calculated using the simplified Bernoulli equation. AVA was calculated using the continuity equation. Stroke volume was calculated by multiplying the LV outflow tract area with the LV outflow tract time-velocity integral. The LV outflow tract diameter was measured in zoomed parasternal long-axis views in early systole at the level of aortic cusp insertion. The LV outflow tract time-velocity integral was recorded from the apical 5-chamber view, with the sample volume positioned %5 mm proximal to the aortic valve. LV dimensions were assessed from parasternal long-axis views by 2-dimensional-guided M mode using the leading-edge method at end diastole and end systole. LVEF was calculated using the Simpson biplane method. LV mass was estimated with an equation based on linear measurements normalized to body surface area (BSA). 13 Left atrial volume was measured at end systole (using the Simpson biplane method) and normalized to BSA. Systolic pulmonary artery pressure was calculated from the maximum peak tricuspid regurgitation velocity using the simplified Bernoulli equation.
Follow-Up and End Points
Median (interquartile range) follow-up was 47 (24-80) months. The inclusion period was from 2000 to 2014. Information on follow-up was obtained yearly on the same period for the entire cohort, by direct patient interview, clinical examination, and/or repeated follow-up letters, questionnaires, and telephone calls to physicians, patients, and (if necessary) next of kin. A total of 246 (97%) of the surviving patients were followed up until the end of the study (2016), with an inclusion date corresponding to the date of baseline echocardiography (3% of patients were lost to follow-up). No patient was censored. The primary end point was all-cause mortality. Secondary end points were cardiovascular mortality and aortic valve replacement (AVR). Clinical decisions on medical management or referral for surgery were made by the Heart Team with the approval of the patient's cardiologist based on the European Society of Cardiology's guidelines 6 when AS had become severe.
Statistical Analysis
Continuous variables are expressed as meanAESD or median (interquartile range), and categorical variables are expressed
Clinical Perspective
What Is New?
• Patients with moderate aortic stenosis (AS) have an increased mortality compared with the general population, mainly related to associated comorbidities.
• Cardiovascular risk factors are frequent in patients with moderate AS and must be appropriately managed.
• The cumulative incidence of aortic valve replacement at 6 years is high, reaching 30%.
What Are the Clinical Implications?
• Patients with moderate AS should be managed for their cardiovascular risk factors.
• Patients with moderate AS and an aortic valve area close to 1 cm 2 should be followed up closely, as aortic valve replacement performed at the stage of severe AS in patients with an indication for surgery is associated with improved survival.
as numbers and percentages. The relationship between baseline continuous variables and the various groups was explored using 1-way ANOVA tests. Mortality analyses were performed using Cox proportional hazards models. A predefined Cox proportional hazards model, including covariates with potential prognostic impact (age, sex, BSA, New York Heart Association class, prior AF, mean transaortic pressure gradient, LVEF, history of myocardial infarction, moderate-tosevere aortic valve calcification, Charlson comorbidity index, and AVR treated as a time-dependent variable), was used for multivariate mortality analyses (all data were complete for these variables). Event ratesAESEs were estimated using the Kaplan-Meier method and compared by 2-sided log-rank tests. Each patient with MAS was matched for the average survival (per year) of all patients of the same age and same sex from our region (Somme, department of 555 551 inhabitants, north of France). Control data were obtained from Somme life tables established on the basis of the 1999 population census, performed by the French Institute of National Statistics, and they represent the survival of the entire Somme general population. 14, 15 Survival rates of patients with MAS were compared with the expected survival of people of the same age and sex in the Somme department. Relative survival was computed as the ratio of observed/expected survival (observed number of deaths in the population with MAS/expected number of deaths in the general population). The limit of statistical significance was P<0.05, and all tests were 2 tailed. Data were analyzed using SPSS 25.0 (SPSS Inc, Chicago, IL).
Results

Baseline Characteristics
The study population consisted of 508 patients: 287 men (56.5%) and 221 women (43.5%), with a meanAESD age of 75AE11 years. Patients were mostly asymptomatic or minimally symptomatic (86.4% in New York Heart Association class 1-2). A total of 398 patients (78.3%) had a history of hypertension, 184 (36.2%) were diabetic, 236 (46.5%) had coronary artery disease, 171 (33.7%) had prior AF, and 39 (7.7%) had a history of myocardial infarction (Table 1) . MeanAESD AVA was 1.2AE0.15 cm 2 , meanAESD transaortic pressure gradient was 24.8AE9 mm Hg, and meanAESD peak aortic jet velocity was 3.2AE0.55 cm/s; and 276 patients (53%) had moderate-to-severe aortic valve calcification. MeanAESD LVEF was 64AE8%, and meanAESD left atrial volume index was 37AE20 mL/m 2 .
Patients who died during follow-up were older (P<0.001), had a smaller BSA (P=0.001), and had more comorbidities (P<0.001) at baseline compared with surviving patients. Deceased patients more often had a history of AF (P<0.001) and more often had moderate-to-severe aortic valve calcification (P=0.016). No differences were observed between surviving and deceased patients in terms of AS severity (all P>0.20), LV dimensions, and LVEF (all P>0.25). Left atrial volume index (P=0.004) was higher in deceased patients ( 
Outcome of MAS
A total of 255 deaths (50.2%) were recorded during follow-up, 101 of which were cardiovascular related (40%). Overall mortality rates were relatively high: 22AE3% at 2 years, 36AE2% at 4 years, and 47AE3% at 6 years of follow-up ( Figure 1 ). The 6-year survival of patients with MAS was lower than the expected survival (53AE2% versus 65% found in 79 patients) was added to the fully adjusted model, it was not independently associated with all-cause (P=0.98) or cardiovascular (P=0.54) mortality.
The bicuspid or tricuspid character of AS, identified using echocardiography, was only available in 300 patients (34 had bicuspid aortic valves and 266 had tricuspid aortic valves). Patients with bicuspid aortic valves were younger (P<0.001) and had a lower Charlson comorbidity index (P=0.038). By Kaplan-Meier analysis, patients with bicuspid valves had better survival than those with tricuspid valves (log-rank P=0.001). However, after adjustment for age and comorbidity index, mortality was similar (P=0.50).
Aortic Valve Surgery
A total of 113 patients (22.2%) underwent AVR during followup: 98 for symptomatic severe AS (77 for dyspnea, 14 for angina, and 7 for syncope), 6 for severe AS with an exercise test showing symptoms related to AS, 4 for asymptomatic very severe AS, 3 for MAS and need for coronary artery bypass grafting, and 2 for MAS associated with aortic aneurysm >55 mm. Thirty-day perioperative mortality was 3.5% (n=4). The meanAESD interval between inclusion and surgery was 37AE22 months. On Kaplan-Meier analysis, the cumulative incidence of surgery was 11AE2% at 24 months, 22AE3% at 48 months, and 31AE3% at 72 months ( Figure 2 ). Operated patients were younger, had more severe AS (all P<0.001), and more often presented moderate-to-severe calcification (P=0.036) and greater LV end-diastolic (P=0.03) and end-systolic (P=0.039) diameters at baseline compared with nonoperated patients (Table 3) . Operated patients had fewer comorbidities (P=0.011) and less often had a history of AF (P=0.014) compared with nonoperated patients (Table 3 ). Results of independent predictors of mortality. BSA indicates body surface area; HR, hazard ratio; MAS, moderate aortic stenosis; NYHA, New York Heart Association. *Treated as a time-dependent variable.
Discussion
The results of the present study show that patients with MAS present numerous cardiovascular risk factors (78.3% had hypertension, 36.2% were diabetics, and 48.3% had dyslipidemia). MAS is associated with a high rate of surgery (31AE3%) at 72 months and with increased mortality compared with the general population, mainly related to comorbidities. Indeed, 255 patients (50.2%) died during follow-up, resulting in a lower survival than the expected survival (6-year survival of 53AE2% versus 65%). On multivariate analysis, age, prior AF, and Charlson comorbidity index were associated with increased all-cause mortality, whereas AVR performed at the stage of severe AS in patients with an indication for surgery was associated with better survival. Some studies focusing on mild-to-moderate AS have reported conflicting results, probably because of the different inclusion criteria used. In the study by Horstkotte and Loogen, 16 the mean interval between diagnosis and AVR was 13.4 years in a population of 142 patients with mild AS. Turina et al reported 100% and 80% 1-and 4-year survivals, respectively, after the diagnosis in a population of patients with mild-to-moderate AS. 17 These 2 studies suggest that mild-to-moderate AS is relatively benign, but they did not distinguish the 2 subgroups of mild AS and MAS. Kennedy et al, 18 in a small population of 66 patients considered to have MAS (with an AVA between 0.7 and 1.2 cm 2 , measured by cardiac catheterization), reported that 14 patients (21%) died of cardiovascular causes during the 35 months after diagnosis. However, some of these patients had severe AS, according to the current definition. 6, 7 In the study by Rosenhek et al, 19 which included 176 patients with mild-to-moderate AS (peak jet velocity between 2.5 and 3.9 m/s), 46% developed severe AS after 48AE19 months of follow-up. These authors reported a 1.8-fold higher mortality than expected, and multivariate analysis showed that moderate-to-severe aortic valve calcification, coronary artery disease, and peak jet velocity were independent predictors of outcome. 19 Otto et al 20 studied the natural history of 123 patients with asymptomatic AS stratified in 3 groups, according to baseline peak aortic jet velocity (<3, 3-4, and >4 m/s). They showed that the likelihood of remaining alive without valve replacement at 2 years was only 21AE18% for a baseline jet velocity >4.0 m/s, compared with 66AE13% for jet velocity between 3.0 and 4.0 m/s and 84AE16% for jet velocity <3.0 m/s. 20 Moreover, the event-free survival of patients with peak jet velocity between 3 and 4 m/s, corresponding to patients with MAS, decreased drastically after 2 to 3 years. This study has undeniably emphasized that patients with MAS are at high risk of AVR. 20 Similar to Otto et al, 20 we observed that mortality and surgery rates increased progressively in patients with MAS and remained relatively low at 2 years (22% mortality and 11% surgery and 61% died, with a mean follow-up of 22 months. They concluded that MAS in this selected veteran population is associated with rapid progression and considerable mortality. This is the only study that has specifically focused on MAS, as defined by current guidelines. 6, 7 Patients with LV dysfunction were not excluded, and the results of this study cannot be generalized, as 99% of patients in this cohort were men with multiple comorbidities. AVR currently remains the only treatment for symptomatic severe AS, because, according to available data, the mean survival after onset of symptoms is only 2 to 3 years. 5, 23 According to current European guidelines, 6 in the presence of significant calcification, mild and MAS should be reevaluated yearly but intervals may be extended to 2 to 3 years in younger patients with mild AS and no significant calcification. US guidelines recommend serial echocardiography every 1 to 2 years for MAS and 3 to 5 years for mild AS. 7 The prognosis of patients with MAS may, therefore, not be as good as previously reported. [18] [19] [20] The results of the present study suggest that patients with MAS should be managed for their 
Conclusion
This study provides important information about MAS, a condition that has not been exclusively studied in the past, as most previous studies mixed mild AS and MAS or used MAS as a comparison group for severe AS. The results show that patients with MAS have an increased mortality compared with the general population. This excess mortality is mainly related to associated comorbidities. Cardiovascular risk factors are frequent in these patients with MAS and must be appropriately managed. The cumulative incidence of AVR at 6 years is high, reaching 30%. Patients with an AVA close to 1 cm 2 should be followed up closely as AVR is associated with improved survival when these patients transition to severe AS and develop indications for surgery during follow-up.
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